Clinical Trial Update: Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis [Phase 2]

View source ↗

Summary

GlaxoSmithKline has withdrawn a Phase 2 placebo-controlled proof-of-concept study of Epelsiban for adenomyosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenomyosis

Drugs mentioned

• Epelsiban (epelsiban)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Adenomyosis | Phase 2 | Status: WITHDRAWN